Tetranor PGDM analyses for the amyotrophic lateral sclerosis: positive and simple diagnosis and evaluation of drug effect |
| |
Authors: | Shinozawa Takao Urade Yoshihiro Maruyama Toshihiko Watabe Daishi |
| |
Affiliation: | aEnvironmental Biotechnology Institute, 447-27 Kakinuma, Kumagaya, Saitama 360-0803, Japan;bDepartment of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan;cFaculty of Engineering, Saitama Institute of Technology, Fusaiji 1690, Fukaya, Saitama 369-0203, Japan |
| |
Abstract: | Amyotrophic lateral sclerosis (ALS) is a late-onset, progressive motor neuronal degenerative disease occurring as sporadically and as a familial disorder. The patients with ALS typically become progressively paralyzed and develop respiratory failure that eventually leads to death within 3–5 years. For this disease, there is no effective diagnostic method and also drug. This report describes a simple and useful diagnostic biomarker for ALS. Our findings suggest that the combination analysis of a metabolite of prostaglandin D2, 11,15-dioxo-9-hydroxy-,2,3,4,5-tetranorprostan-1,20-dioic acid (tetranor PGDM and tPGDM) with creatinine is the diagnostic approach for ALS with high accuracy. tPGDM has the potential to be an important diagnostic tool in the pre-symptomatic stages and progression evaluation of ALS, and also to be a biomarker for the evaluation of drug effect. |
| |
Keywords: | Amyotrophic lateral sclerosis (ALS) Diagnosis Tetranor PGDM Creatinine Radicut (edaravone) |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|